Cancer researchers have high hopes for a new therapy for patients with certain types of lymphoma and leukemia.
PCI-32765 is a new drug being assessed in a Phase I clinical trial at the Virginia G. Piper Cancer Center in collaboration with the Clinical Division of the Translational Genomics Research Institute (TGen).
This is one of 35 such trials under way through a partnership between the Virginia G. Piper Cancer Center at Scottsdale Healthcare and TGen, which enables molecular and genomic discoveries to reach patients through Phase I trials as quickly as possible.
"Progress in developing new treatments for cancer has been painfully slow as only 2-4 percent of all cancer patients enroll in clinical trials. This is especially true for uncommon cancers such as leukemia's and lymphomas," said Dr. Raoul Tibes, Director of the Hematological Malignancies Program at the Virginia G. Piper Cancer Center and an Associate Investigator at TGen.
Clinical trials test the safety and effectiveness of new drugs prior to approval by the U.S. Food and Drug Administration. Participants are volunteers for whom other cancer treatments have failed. Arizona is one of many states in which clinical trials often are covered by health insurance.
"This study is going very well. It is a very promising agent,'' Dr. Tibes said of PCI-32765, which uniquely targets the molecular abnormalities of lymphoma cells. "This is a recently identified cancer mechanism that we are going after with this drug in lymphoma cells."
Bruton-tyrosine-kinase, or Btk, is an enzyme needed to maintain B-lymphocytes function. B- lymphocytes are the cells that make antibodies for the immune system.
Too little Btk causes a disease called Bruton's agammaglobulinemia, in which the B-lymphocytes fail to mature and produce antibodies, leading to infections.
Too much Btk is involved in constantly stimulating the proliferation and spread of lymphoma and leukemia cells.
PCI-32765, produced by Pharmacyclics of Sunnyvale, Calif., inhibits Btk. Preclinical studies showed PCI-32765 arrested cancer cell growth and caused cancer cell death.
"This is the Yin and Yang of two diseases," said Dr. Tibes. In one there is not enough Btk; in the other, too much. "We are exploiting a natural occurring phenomenon, an enzyme that is turned around in cancer, and now we have a drug against it."
Dr. Tibes, the principal investigator for the clinical trial, said PCI-32765 is at the frontier of research and offers a new therapy option for patients with advanced lymphomas and chronic lymphocytic leukemia.
Patients with a variety of lymphomas can participate in the clinical trial, including those with aggressive diffuse large B-Cell and mantle cell lymphoma, as well as patients with follicular lymphoma.
"Perhaps there is a genetic context under which certain patients may be more responsive. We want to find those patients and explore the possibilities for their benefit in this ongoing study,'' said Dr. Ramesh K. Ramanathan, research medical director.
About the Virginia G. Piper Cancer Center at Scottsdale Healthcare
The Virginia G. Piper Cancer Center at Scottsdale Healthcare offers prevention, diagnosis, treatment, research and support services in its facilities at the Scottsdale Healthcare Shea Medical Center, attracting patients from across Arizona and the U.S. Scottsdale Healthcare is the not-for-profit parent organization of the Scottsdale Healthcare Shea Medical Center, Scottsdale Healthcare Osborn Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center, Scottsdale Clinical Research Institute and Scottsdale Healthcare Foundation. For additional information, visit www.shc.org.Press Contact:
Steve Yozwiak | EurekAlert!
A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau
On the way to developing a new active ingredient against chronic infections
18.08.2017 | Deutsches Zentrum für Infektionsforschung
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences